Modulating oxytocin activity and plasma stability by disulfide bond engineering

Journal of Medicinal Chemistry

Volumn 53, Issue 24, 2010, Pages 8585-8596

  Muttenthaler, Markus ^a   Andersson, Asa ^a   De Araujo, Aline D ^a   Dekan, Zoltan ^a   Lewis, Richard J ^a   Alewood, Paul F ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATHIONINE; OXYTOCIN; OXYTOCIN DERIVATIVE; OXYTOCIN RECEPTOR; SELENIDE; SELENYLSULFIDE; TELLURIUM DERIVATIVE; THIOESTER; UNCLASSIFIED DRUG; VASOPRESSIN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; DISULFIDE BOND; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; ENGINEERING; MOLECULAR STABILITY; NONHUMAN;

ALKYLATION; DISULFIDES; DRUG STABILITY; HALF-LIFE; HUMANS; ORGANOMETALLIC COMPOUNDS; ORGANOSELENIUM COMPOUNDS; OXIDATION-REDUCTION; OXYTOCIN; PEPTIDOMIMETICS; RADIOLIGAND ASSAY; RECEPTORS, OXYTOCIN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFIDES; TELLURIUM;

EID: 78650364983     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100989w     Document Type: Article

References (81)

1. Sato, A. K.; Viswanathan, M.; Kent, R. B.; Wood, C. R. Therapeutic peptides: Technological advances driving peptides into development Curr. Opin. Biotechnol. 2006, 17, 638-642
2. Reichert, J. Therapeutic Peptides in Clinical Study in 2000-07 Nearly Doubled 1990s Rate; Tufts Center for the Study of Drug Development, Boston, 2009; pp 1-4.
3. Kumar, T. R. S.; Soppimath, K.; Nachaegari, S. K. Novel delivery technologies for protein and peptide therapeutics Curr. Pharm. Biotechnol. 2006, 7, 261-276
4. Hamman, J. H.; Enslin, G. M.; Kotze, A. F. Oral delivery of peptide drugs: Barriers and developments BioDrugs 2005, 19, 165-177
5. Craik, D. J.; Adams, D. J. Chemical modification of conotoxins to improve stability and activity ACS Chem. Biol. 2007, 2, 457-468
6. Claybaugh, J. R.; Uyehara, C. F. T. Metabolism of neurohypophysial hormones Ann. N. Y. Acad. Sci. 1993, 689, 250-268
7. Hong, S. Y.; Oh, J. E.; Lee, K. H. Effect of D-amino acid substitution on the stability, the secondary structure, and the activity of membrane-active peptide Biochem. Pharmacol. 1999, 58, 1775-1780
8. Ember, J. A.; Sanderson, S. D.; Taylor, S. M.; Kawahara, M.; Hugli, T. E. Biological activity of synthetic analogs of C5a anaphylatoxin J. Immunol. 1992, 148, 3165-3173
9. Clark, R. J.; Fischer, H.; Dempster, L.; Daly, N. L.; Rosengren, K. J.; Nevin, S. T.; Meunier, F. A.; Adams, D. J.; Craik, D. J. Engineering stable peptide toxins by means of backbone cyclization: Stabilization of the α-conotoxin MII Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 13767-13772
10. Hill, P. S.; Smith, D. D.; Slaninova, J.; Hruby, V. J. Bicyclization of a weak oxytocin agonist produces a highly potent oxytocin antagonist J. Am. Chem. Soc. 1990, 112, 3110-3113
11. Werle, M.; Bernkop-Schnuerch, A. Strategies to improve plasma half life time of peptide and protein drugs Amino Acids 2006, 30, 351-367
12. Bauer, W.; Briner, U.; Doepfner, W.; Haller, R.; Huguenin, R.; Marbach, P.; Petcher, T. J.; Pless, J. SMS 201-995: A very potent and selective octapeptide analog of somatostatin with prolonged action Life Sci. 1982, 31, 1133-1140
13. Janknegt, R. A.; Zweers, M. M.; Delaere, K. P. J.; Kloet, A. G.; Khoe, S. G. S.; Arendsen, H. J. Oral desmopressin as a new treatment modality for primary nocturnal enuresis in adolescents and adults: A double-blind, randomized, multicenter study J. Urol. (Baltimore) 1997, 157, 513-517
14. Zaoral, M.; Kolc, J.; Sorm, F. Amino acids and peptides. LXXI. Synthesis of 1-deamino-8-D-gamma-aminobutyrine vasopressin, 1-deamino-8-D-lysine vasopressin, and 1-deamino-8-D-arginine vasopressin Collect. Czech. Chem. Commun. 1967, 32, 1250-1257
15. Sawyer, W. H.; Acosta, M.; Manning, M. Structural changes in the arginine vasopressin molecule that prolong its antidiuretic action Endocrinology 1974, 95, 140-149
16. Barberis, C.; Morin, D.; Durroux, T.; Mouillac, B.; Guillon, G.; Seyer, R.; Hibert, M.; Tribollet, E.; Manning, M. Molecular pharmacology of AVP and OT receptors and therapeutic potential Drug News Perspect. 1999, 12, 279-292
17. Hargittai, B.; Sole, N. A.; Groebe, D. R.; Abramson, S. N.; Barany, G. Chemical syntheses and biological activities of lactam analogs of α-conotoxin SI J. Med. Chem. 2000, 43, 4787-4792
18. Smith, C. W.; Walter, R.; Moore, S.; Makofske, R. C.; Meienhofer, J. Replacement of the disulfide bond in oxytocin by an amide group. Synthesis and some biological properties of (cyclo-(1- l -aspartic acid,6- l -α,β-diaminopropionic acid))oxytocin J. Med. Chem. 1978, 21, 117-120
19. MacRaild, C. A.; Illesinghe, J.; van Lierop, B. J.; Townsend, A. L.; Chebib, M.; Livett, B. G.; Robinson, A. J.; Norton, R. S. Structure and Activity of (2,8)-Dicarba-(3,12)-cystino α-ImI, an α-Conotoxin Containing a Nonreducible Cystine Analogue J. Med. Chem. 2009, 52, 755-762
20. Yamanaka, T.; Hase, S.; Sakakibara, S.; Schwartz, I. L.; Dubois, B. M.; Walter, R. Crystalline deamino-dicarba-oxytocin. Preparation and some pharmacological properties Mol. Pharmacol. 1970, 6, 474-480
21. Stymiest, J. L.; Mitchell, B. F.; Wong, S.; Vederas John, C. Synthesis of oxytocin analogues with replacement of sulfur by carbon gives potent antagonists with increased stability J. Org. Chem. 2005, 70, 7799-7809
22. Bondebjerg, J.; Grunnet, M.; Jespersen, T.; Meldal, M. Solid-phase synthesis and biological activity of a thioether analogue of conotoxin G1 ChemBioChem 2003, 4, 186-194
23. Oesapay, G.; Prokai, L.; Kim, H.-S.; Medzihradszky, K. F.; Coy, D. H.; Liapakis, G.; Reisine, T.; Melacini, G.; Zhu, Q.; Wang, S. H. H.; Mattern, R.-H.; Goodman, M. Lanthionine-Somatostatin Analogs: Synthesis, Characterization, Biological Activity, and Enzymic Stability Studies J. Med. Chem. 1997, 40, 2241-2251
24. Schramme, A. R.; Pinto, C. R. F.; Davis, J.; Whisnant, C. S.; Whitacre, M. D. Pharmacokinetics of carbetocin, a long-acting oxytocin analogue, following intravenous administration in horses Equine Vet. J. 2008, 40, 658-661
25. Hunter, D. J. S.; Schulz, P.; Wassenaar, W. Effect of carbetocin, a long-acting oxytocin analog on the postpartum uterus Clin. Pharmacol. Ther. (St. Louis) 1992, 52, 60-67
26. Sweeney, G.; Holbrook, A. M.; Levine, M.; Yip, M.; Alfredsson, K.; Cappi, S.; Ohlin, M.; Schulz, P.; Wassenaar, W. Pharmacokinetics of carbetocin, a long-acting oxytocin analog, in nonpregnant women Curr. Ther. Res. 1990, 47, 528-540
27. Muttenthaler, M.; Nevin, S. T.; Grishin, A. A.; Ngo, S. T.; Choy, P. T.; Daly, N. L.; Hu, S.-H.; Armishaw, C. J.; Wang, C.-I. A.; Lewis, R. J.; Martin, J. L.; Noakes, P. G.; Craik, D. J.; Adams, D. J.; Alewood, P. F. Solving the α-Conotoxin Folding Problem: Efficient Selenium-Directed On-Resin Generation of More Potent and Stable Nicotinic Acetylcholine Receptor Antagonists J. Am. Chem. Soc. 2010, 132, 3514-3522
28. Walewska, A.; Zhang, M.-M.; Skalicky Jack, J.; Yoshikami, D.; Olivera Baldomero, M.; Bulaj, G. Integrated oxidative folding of cysteine/selenocysteine containing peptides: improving chemical synthesis of conotoxins Angew. Chem., Int. Ed. Engl. 2009, 48, 2221-2224
29. Gowd, K. H.; Yarotskyy, V.; Elmslie, K. S.; Skalicky, J. J.; Olivera, B. M.; Bulaj, G. Site-Specific Effects of Diselenide Bridges on the Oxidative Folding of a Cystine Knot Peptide, ω-Selenoconotoxin GVIA Biochemistry 2010, 49, 2741-2752
30. Metanis, N.; Keinan, E.; Dawson, P. E. Synthetic Seleno-Glutaredoxin 3 Analogues Are Highly Reducing Oxidoreductases with Enhanced Catalytic Efficiency J. Am. Chem. Soc. 2006, 128, 16684-16691
31. Armishaw, C. J.; Daly, N. L.; Nevin, S. T.; Adams, D. J.; Craik, D. J.; Alewood, P. F. α-Selenoconotoxins, a New Class of Potent α7 Neuronal Nicotinic Receptor Antagonists J. Biol. Chem. 2006, 281, 14136-14143
32. Fiori, S.; Pegoraro, S.; Rudolph-Böhner, S.; Cramer, J.; Moroder, L. Synthesis and conformational analysis of apamin analogues with natural and non-natural cystine/selenocystine connectivities Biopolymers 2000, 53, 550-564
33. Pegoraro, S.; Fiori, S.; Rudolph-Böhner, S.; Watanabe, T. X.; Moroder, L. Isomorphous replacement of cystine with selenocystine in endothelin: Oxidative refolding, biological and conformational properties of [Sec3, Sec11, Nle7]-endothelin-1 J. Mol. Biol. 1998, 284, 779-792
34. Muttenthaler, M.; Alewood, P. F. Selenopeptide chemistry J. Pept. Sci. 2008, 14, 1223-1239
35. Muttenthaler, M.; Alewood, P. F. Selenocystine Peptides - Synthesis, Folding and Applications. In Oxidative Folding of Peptides and Proteins; Johannes, B.; Moroder, L., Eds.; The Royal Society of Chemistry: Cambridge, 2008; pp 396-418.
36. Gimpl, G.; Fahrenholz, F. The oxytocin receptor system: structure, function, and regulation Physiol. Rev. 2001, 81, 629-683
37. Zingg, H. H.; Laporte, S. A. The oxytocin receptor Trends Endocrinol. Metabol. 2003, 14, 222-227
38. Donaldson, Z. R.; Young, L. J. Oxytocin, vasopressin, and the neurogenetics of sociality Science 2008, 322, 900-904
39. Reversi, A.; Cassoni, P.; Chini, B. Oxytocin receptor signaling in myoepithelial and cancer cells J. Mammary Gland Biol. Neoplasia 2005, 10, 221-229
40. Chini, B.; Chinol, M.; Cassoni, P.; Papi, S.; Reversi, A.; Areces, L.; Marrocco, T.; Paganelli, G.; Manning, M.; Bussolati, G. Improved radiotracing of oxytocin receptor-expressing tumours using the new [111In]-DOTA-Lys8-deamino- vasotocin analogue Br. J. Cancer 2003, 89, 930-936
41. Green, J. J.; Hollander, E. Autism and oxytocin: New developments in translational approaches to therapeutics Neurotherapeutics 2010, 7, 250-257
42. Wood, S. P.; Tickle, I. J.; Treharne, A. M.; Pitts, J. E.; Mascarenhas, Y.; Li, J. Y.; Husain, J.; Cooper, S.; Blundell, T. L. Crystal structure analysis of deamino-oxytocin: conformational flexibility and receptor binding Science 1986, 232, 633-636
43. Rose, J. P.; Wu, C.-K.; Hsiao, C.-D.; Breslow, E.; Wang, B.-C. Crystal structure of the neurophysin-oxytocin complex Nat. Struct. Biol. 1996, 3, 163-169
44. Bhaskaran, R.; Chuang, L. C.; Yu, C. Conformational properties of oxytocin in dimethyl sulfoxide solution: NMR and restrained molecular dynamics studies Biopolymers 1992, 32, 1599-1608
45. Meraldi, J. P.; Hruby, V. J.; Brewster, A. I. R. Relative conformational rigidity in oxytocin and [1-penicillamine]oxytocin: A proposal for the relation of conformational flexibility to peptide hormone agonism and antagonism Proc. Natl. Acad. Sci. U.S.A. 1977, 74, 1373-1377
46. Smith, C. W.; Ferger, M. F. Synthesis and some pharmacological properties of five analogs of oxytocin having l -homocysteine in position 6 J. Med. Chem. 1976, 19, 250-254
47. Stymiest, J. L.; Mitchell, B. F.; Wong, S.; Vederas, J. C. Synthesis of biologically active dicarba analogues of the peptide hormone oxytocin using ring-closing metathesis Org. Lett. 2003, 5, 47-49
48. Keller, O.; Rudinger, J. Synthesis of (1,6-alpha,alpha′- diaminosuberic acid)oxytocin ('dicarba-oxytocin') Helv. Chim. Acta 1974, 57, 1253-1259
49. Schnölzer, M.; Alewood, P.; Jones, A.; Alewood, D.; Kent, S. B. H. In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences Int. J. Pept. Protein Res. 1992, 40, 180-193
50. Muttenthaler, M.; Ramos, Y. G.; Feytens, D.; de Araujo, A. D.; Alewood, P. F. p-Nitrobenzyl protection for cysteine and selenocysteine: A more stable alternative to the acetamidomethyl group Biopolymers 2010, 94, 423-432
51. Mayer, J. P.; Heil, J. R.; Zhang, J.; Munson, M. C. An alternative solid-phase approach to C1-oxytocin Tetrahedron Lett. 1995, 36, 7387-7390
52. Zhu, X.; Schmidt, R. R. Efficient synthesis of differently protected lanthionines via beta-bromoalanine derivatives Eur. J. Org. Chem. 2003, 4069-4072
53. Albericio, F.; Cases, M.; Alsina, J.; Triolo, S. A.; Carpino, L. A.; Kates, S. A. On the use of PyAOP, a phosphonium salt derived from HOAt, in solid-phase peptide synthesis Tetrahedron Lett. 1997, 38, 4853-4856
54. Isidro-Llobet, A.; Guasch-Camell, J.; Alvarez, M.; Albericio, F. p-Nitrobenzyloxycarbonyl (pNZ) as a temporary Nalpha-protecting group in orthogonal solid-phase peptide synthesis - Avoiding diketopiperazine and aspartimide formation Eur. J. Org. Chem. 2005, 3031-3039
55. Trinquet, E.; Fink, M.; Bazin, H.; Grillet, F.; Maurin, F.; Bourrier, E.; Ansanay, H.; Leroy, C.; Michaud, A.; Durroux, T.; Maurel, D.; Malhaire, F.; Goudet, C.; Pin, J.-P.; Naval, M.; Hernout, O.; Chretien, F.; Chapleur, Y.; Mathis, G. D-myo-Inositol 1-phosphate as a surrogate of D-myo-inositol 1,4,5-tris phosphate to monitor G protein-coupled receptor activation Anal. Biochem. 2006, 358, 126-135
56. Kimura, T.; Tanizawa, O.; Mori, K.; Brownstein, M. J.; Okayama, H. Structure and expression of a human oxytocin receptor Nature (London) 1992, 356, 526-529
57. Dutertre, S.; Croker, D.; Daly, N. L.; Andersson, A.; Muttenthaler, M.; Lumsden, N. G.; Craik, D. J.; Alewood, P. F.; Guillon, G.; Lewis, R. J. Conopressin-T from Conus Tulipa Reveals an Antagonist Switch in Vasopressin-like Peptides J. Biol. Chem. 2008, 283, 7100-7108
58. Manning, M.; Stoev, S.; Chini, B.; Durroux, T.; Mouillac, B.; Guillon, G. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: Research tools and potential therapeutic agents Prog. Brain Res. 2008, 170, 473-512
59. Zaoral, M.; Krchnak, V. Amino acids and peptides. Part CXLII. Cyclooxytocin, an oxytocin analog with an enhanced stability of the secondary structure Collect. Czech. Chem. Commun. 1977, 42, 3500-3509
60. Orcel, H.; Albizu, L.; Perkovska, S.; Durroux, T.; Mendre, C.; Ansanay, H.; Mouillac, B.; Rabie, A. Differential coupling of the vasopressin V1b receptor through compartmentalization within the plasma membrane Mol. Pharmacol. 2009, 75, 637-647
61. Kenakin, T. Pharmacologic Analysis of Drug-Receptor Interaction, 3 rd ed.; Lippincott-Raven Publishers: Philadelphia, 1997.
62. Kenakin, T. Ligand-selective receptor conformations revisited: the promise and the problem Trends Pharmacol. Sci. 2003, 24, 346-354
63. Cottet, M.; Albizu, L.; Perkovska, S.; Jean-Alphonse, F.; Rahmeh, R.; Orcel, H.; Mejean, C.; Granier, S.; Mendre, C.; Mouillac, B.; Durroux, T. Past, present and future of vasopressin and oxytocin receptor oligomers, prototypical GPCR models to study dimerization processes Curr. Opin. Pharmacol. 2010, 10, 59-66
64. Kobilka, B. K.; Deupi, X. Conformational complexity of G-protein-coupled receptors Trends Pharmacol. Sci. 2007, 28, 397-406
65. Smith, C. W.; Botos, C. R.; Skala, G.; Walter, R. Conformation-activity studies of oxytocin. Effects of structural modifications at corner positions of the β-turns on the uterotonic activity J. Med. Chem. 1977, 20, 1457-1460
66. Nicke, A.; Wonnacott, S.; Lewis, R. J. α-Conotoxins as tools for the elucidation of structure and function of neuronal nicotinic acetylcholine receptor subtypes Eur. J. Biochem. 2004, 271, 2305-2319
67. Barth, T.; Krejci, I.; Vaneckova, J.; Jost, K.; Rychlik, I. Prolonged action of deamino-carba analogs of oxytocin on the rat uterus in vivo Eur. J. Pharmacol. 1974, 25, 67-70
68. Small, C. W.; Watkins, W. B. Glutathione-oxytocin transhydrogenase of human placental origin with specificity towards neurohypophysial hormones Nature (London, U. K.) 1974, 251, 237-239
69. Suska-Brzezinska, E.; Fruhaufova, L.; Barth, T.; Rychlik, I.; Jost, K.; Sorm, F. Inactivation of deamino-carba analogs of oxytocin in the rat uterus, liver, and kidney Collect. Czech. Chem. Commun. 1972, 37, 2289-2294
70. Besse, D.; Siedler, F.; Diercks, T.; Kessler, H.; Moroder, L. The redox potential of selenocystine in unconstrained cyclic peptides Angew. Chem., Int. Ed. Engl. 1997, 36, 883-885 (Pubitemid 27222055)
71. Powell, M. F.; Stewart, T.; Otvos, L., Jr.; Urge, L.; Gaeta, F. C. A.; Sette, A.; Arrhenius, T.; Thomson, D.; Soda, K.; Colon, S. M. Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum Pharm. Res. 1993, 10, 1268-1273
72. Powell, M. F.; Grey, H.; Gaeta, F.; Sette, A.; Colon, S. Peptide stability in drug development: A comparison of peptide reactivity in different biological media J. Pharm. Sci. 1992, 81, 731-735
73. Anderson, N. L.; Anderson, N. G. The human plasma proteome. History, character, and diagnostic prospects Mol. Cell. Proteomics 2002, 1, 845-867
74. Hruby, V. J. Designing peptide receptor agonists and antagonists Nat. Rev. Drug Discovery 2002, 1, 847-858
75. Smith, D. D.; Slaninova, J.; Hruby, V. J. Structure-activity studies of a novel bicyclic oxytocin antagonist J. Med. Chem. 1992, 35, 1558-1563
76. Hruby, V. J.; Rockway, T. W.; Viswanatha, V.; Chan, W. Y. Pharmacological, conformational and dynamic properties of cycloleucine-2 analogues of oxytocin and [1-penicillamine]oxytocin Int. J. Pept. Protein Res. 1983, 21, 24-34
77. Hruby, V. J. Relation of conformation to biological activity in oxytocin, vasopressin and their analogs Top. Mol. Pharmacol. 1981, 1, 99-126
78. Mustapa, M. F. M.; Harris, R.; Esposito, D.; Chubb, N. A. L.; Mould, J.; Schultz, D.; Driscoll, P. C.; Tabor, A. B. Synthesis of a Cyclic Peptide Containing Norlanthionine: Effect of the Thioether Bridge on Peptide Conformation J. Org. Chem. 2003, 68, 8193-8198
79. Alewood, P.; Alewood, D.; Miranda, L.; Love, S.; Meutermans, W.; Wilson, D. Rapid in situ neutralization protocols for Boc and Fmoc solid-phase chemistries Methods Enzymol. 1997, 289, 14-29
80. Moroder, L. Isosteric replacement of sulfur with other chalcogens in peptides and proteins J. Pept. Sci. 2005, 11, 187-214
81. 2 Acta Crystallogr., Sect. C: Cryst. Struct. Commun. 1984, C40, 1011-1012